A public repository of the data will be held in: [www.datadryad.org/stash/](http://www.datadryad.org/stash/) (DOI <https://doi.org/10.5061/dryad.sbcc2fr22>). Direct download of the data are available from: <https://datadryad.org/stash/share/1HiLI_7GxvhUu2wIAQNCCUK5ScptshXoJuCggR4g9Js>. An independent researcher could contact with the Ethics Committee (E-Mail: <ceic@fjd.es>), for full access to confidential data, after requesting personal authorization.

Background {#sec006}
==========

Sjögren's syndrome (SS) is systemic autoimmune disease characterized by chronic lymphocytic inflammation of ductal epithelial structures. The disease affects principally the exocrine glands, in particular the lacrimal and salivary glands, causing dryness of mucosal surfaces--termed sicca syndrome--and glandular parenchymal damage. The pathogenesis of SS is poorly understood, and manifestations are heterogeneous \[[@pone.0224772.ref001]\]. Accordingly, there is increasing interest in its systemic involvement \[[@pone.0224772.ref002]\] and how to reach a precise diagnosis using molecular profiling \[[@pone.0224772.ref003]--[@pone.0224772.ref004]\].

Interstitial lung disease (ILD) remains one of most frequent pulmonary complications in primary SS and sub-clinical disease is even more common \[[@pone.0224772.ref005]--[@pone.0224772.ref006]\]. Pulmonary disease is a singular clinical and histopathological scenario among the organ-specific SS involvement and leads to increased risk of mortality \[[@pone.0224772.ref007]--[@pone.0224772.ref008]\]; and it is considered in the high systemic activity domain of the European League against Rheumatism (EULAR) Sjögren's syndrome disease activity index (ESSDAI).

An accurate differential diagnosis of ILD, obstructive disease, bronchial hyper-responsiveness, bronchiolitis, bronchiectasis or xerotrachea can be challenging \[[@pone.0224772.ref009]\]. High-resolution chest computer tomography (HRCT) is currently considered the gold standard imaging modality in confirming a diagnosis of SS and has clear improvements over classical chest x-ray \[[@pone.0224772.ref010]--[@pone.0224772.ref012]\]. It also allows for the discrimination and estimation of the extent of the ILD and can inform on treatment decisions. Likewise, semiquantitative CT (SQCT) assessment, such as the Goh \[[@pone.0224772.ref013]\] and Tauli \[[@pone.0224772.ref014]\] visual scores, can estimate ILD severity--in terms of limited or extensive disease--in autoimmune systemic diseases. However, these classification systems suffer from intra- and interobserver variability \[[@pone.0224772.ref015]\]. Quantitative CT (QCT) analysis is a promising tool to assess primary or secondary ILD and its extent. It is based on software providing highly accurate and operator-independent measurements, termed QCT indices \[[@pone.0224772.ref016]\], which have been rapidly developed and validated in specific clinical settings, including systemic autoimmune diseases \[[@pone.0224772.ref017]\].

To the best of our knowledge, there have been no studies focused on the use of QCT for SS with ILD. Herein, we designed a study to evaluate whether QCT indices have clinical utility to screen for ILD and to appraise differences between limited and extensive ILD.

Methods {#sec007}
=======

We performed a multicenter, cross-sectional, and retrospective study in patients with SS enrolled in four university-affiliated centers.

The following inclusion criteria were applied: 2016 American College of Rheumatology (ACR)/EULAR criteria \[[@pone.0224772.ref018]\], a chest CT scan ordered by a primary care physician for any reason, and age older than 18 years. The exclusion criteria included those specified by the 2016 ACR/EULAR consensus, including IgG4 disease, any immunosuppressive therapy with any biological agent in the last 3 months, or methotrexate or leflunomide in the year prior to study inclusion. Prednisone (or equivalent) at a dose ≤7.5 mg (on a tapering plan only) or low-dose hydroxychloroquine was allowed. The research protocol was approved by the local ethics committees and was conducted in accordance with the tenets of the Helsinki Declaration. The protocol was developed following the STROBE statement \[[@pone.0224772.ref019]\]

The following data were collected from all patients: demographic variables (age, sex), date of disease onset, symptoms suspicion of pulmonary disease, smoking habit, chest CT scan, pulmonary function tests \[diffusing capacity of carbon monoxide (DLco), DLco divided by alveolar volume (DLco/VA), forced vital capacity (FVC) and total volume capacity (TLC)\], and autoantibodies profile (SSA/Ro, SSB/La). The laboratories of all the participating centers used the same methodology, which was adopted from the current standards of the American Thoracic Society/European Respiratory Society.

A DICOM (digital imaging and communications in medicine) viewer, open-source software (Horos **[www.horosproject.org](http://www.horosproject.org/)**) was used for analyses and the following QCT indices were obtained after scan processing: kurtosis (Kurt), mean lung attenuation (MLA), skewness (Skew) and standard deviation (Sdev). The entire procedure including the lung segmentation algorithm was performed as described previously \[[@pone.0224772.ref016]\]. Accordingly, the region of interest between -950 HU and 400 HU was considered as 'pulmonary parenchyma' (namely, lung parenchyma without vessels or bronchioles and not affected by fibrosis). Those voxels included in the whole lung volume with higher HU values were identified as non-parenchymal structures. The QTC indices were calculated according to these definitions, as parenchymal (i.e., pKurt, pSkew, etc.) and total (i.e., tKurt, tSkew, etc.) QTC. These indices are based on the histograms obtained from the computed analysis of the volumetric region of interest \[[@pone.0224772.ref017], [@pone.0224772.ref020]\].

All CT images were centrally and blindly reviewed by the same board-certified radiologists (MS, NS) and QCT indices were then calculated. The SQCT assessment was carried out to calculate both Goh and Taouli scores for each CT scan. On the basis of the SQCT assessment, two groups were established: patients with SS and with/without ILD.

Data were reported as mean and SD for continuous variables and numbers and percentages for categorical variables. The Kolgomorov-Smirnov test was used to check the assumption of normality of the continuous variables. Differences between subgroups were analyzed using a non-parametric test, as appropriate. The Spearman rank test was used to determine correlations of QCT indices with SQCT scores, pulmonary function tests, and the other collected variables. A Youden index, according to the area under the curve, was run to select the best cut-off point value of QCT indices to assess the ILD.

The research was approved by the ethics committee of Fundación Jiménez Díaz, Madrid.

Approval Number: PIC 17--2017 The data were analyzed anonymously.

A two-tailed probability of p\<0.05 was considered statistically significant. All analyses were conducted using SPSS 20.0 (Chicago, IL, USA) and R (version 3.5.2) statistical software package (**<http://www.R-project.org/>**) (Vienna, Austria).

Results {#sec008}
=======

A total of 102 patients were enrolled between January 2017 and September 2018. Patient characteristics are listed in [Table 1](#pone.0224772.t001){ref-type="table"}.

10.1371/journal.pone.0224772.t001

###### Baseline characteristics of the patients with Sjögren's syndrome.

![](pone.0224772.t001){#pone.0224772.t001g}

  ---------------------------------------------------------------------------------------------------------------------
                                                                Total cohort   SS without ILD   SS-ILD        p-value
  ------------------------------------------------------------- -------------- ---------------- ------------- ---------
  N                                                             102            66               36            \-

  Age, median (yrs) (95% CI)                                    69\            68\              69\           nss
                                                                (65--71)       (63--71)         (63--74)      

  Sex (M:F)                                                     7:95           3:63             4:32          nss

  Smoker (no:former:yes)[\*](#t001fn002){ref-type="table-fn"}   74:8:11        47:8:4           27:0:7        nss

  Disease duration, median (yrs) (95% CI)                       4\             3\               5\            nss
                                                                (3--5)         (2--5)           (3--7)        

  pSS prevalence (%)                                            79             83               72            nss

  Onset symptoms (sicca:dyspnoea:other)                         51:27:24       41:7:18          10:20:6       \<0.001

  Antibodies Ro/SSA\                                            52             47               63            nss
  prevalence (%)                                                                                              

  Antibodies La/SSB\                                            25             21               31            nss
  prevalence (%)                                                                                              

  FVC (%) (95% CI) [\*\*](#t001fn003){ref-type="table-fn"}      97\            108\             94\           0.03
                                                                (93--108)      (93--116)        (83--99)      

  DLco (%) (95% CI) [\*\*\*](#t001fn004){ref-type="table-fn"}   71\            82\              63\           0.01
                                                                (62--81)       (73--87)         (53--71)      

  ILD pattern (NSIP:UIP:Other)                                  \-             \-               27:6:3        \-

  Goh score (95% CI)                                            0              0                12,5\         \-
                                                                                                (7.7--25.3)   

  Taouli score (95% CI)                                         0              0                8,0\          \-
                                                                                                (5.7--11.0)   
  ---------------------------------------------------------------------------------------------------------------------

Abbreviations: M, male; F, female; CI, confidence interval; pSS, primary SS; ILD, interstitial lung disease; Nss, not statistically significant; FVC, forced vital capacity; DLCO, diffusion of lung CO; TLC, total lung capacity; FEV1, forced expiratory volume in first second; NSIP, non-specific interstitial pneumonia; UIP, usual interstitial pneumonia.

\* 9/102 patients data missing.

\*\* 41/102 patients data missing.

\*\*\* 58/102 patients data missing

The diseases associated to the development of SS, secondary SS, were: rheumatoid arthritis (5,9%), systemic lupus erythematosus (2%), systemic sclerosis (12,7%), and undifferentiated connective tissue disease (9,8%). Of the, just 10 cases have associated ILD.

Pulmonary function tests were incomplete in more than half of all patients (41% and 58% of patients did not have FCV and DLco data, respectively). No differences were found for patients with SS with ILD (SS-ILD) and those without ILD in terms of age, disease duration and autoimmune profile. The most common onset symptom in the SS-ILD group was dyspnea (52%), whereas mouth or eye dryness was the most common onset symptom in the SS without ILD group (59%). Pulmonary function tests showed that %FCV and %DLco were lower in the SS-ILD group than in the SS without ILD group (p = 0.03 and p = 0.01, respectively). As expected, there was a strong correlation between the Goh and Taouli scores (rho = 0.98; p\<0.001). [Table 2](#pone.0224772.t002){ref-type="table"}.

10.1371/journal.pone.0224772.t002

###### Correlations of quantitative indices and semiquantiative methods and lung function tests.

![](pone.0224772.t002){#pone.0224772.t002g}

  -------------------------------------------------------------------------------------------------------------
                    *pKurt*     *pMLA*   *pSdev*     *pSkew*     *tKurt*     *tMLA*      *tSdev*    *tSkew*
  ----------------- ----------- -------- ----------- ----------- ----------- ----------- ---------- -----------
  *Goh score*\      -0,58       0.48     0.55        -0,56       -0,62       0.44        0.36       -0,65
  *N = 102*                                                                                         

  *Taouli score*\   -0.58       0.48     0.56        -0.55       -0.63       0.45        0.36       -0.65
  *N = 102*                                                                                         

  *PTF FVC (%)*\    0.52        -0.55    -0.48       0.52        0.49        -0.41       -0.33\     0.49
  *N = 61*                                                                               p = 0.03   

  *PRF DLco*\       0.61        -0.54    -0.58       0.6         0.39\       -0.51       -0.22\     0.46\
  *N = 44*                                                       p = 0.009               ns         p = 0.002

  *PFT TLC*\        0.77        -0.64    -0.71       0.76        0.63        -0.49       -0.34\     0.70
  *N = 27*                                                                               ns         

  *PFT FEV1 (%)*\   0.4\        -0.43    -0.34\      0.39\       0.48        -0.41\      -0.29\     0.49
  *N = 61*          p = 0.002            p = 0.007   p = 0.002               p = 0.001   p = 0.03   
  -------------------------------------------------------------------------------------------------------------

All correlations have a p-value \<0.001, except where specified. Abbreviations. ILD, interstitial lung disease; p(X), pulmonary quantitative indices, t(X), total quantitative indices. Kurtosis (Kurt), Sweetness (Skew), standard deviation (Sdev) and mean lung attenuation (MLA). PFT, pulmonary function test; FVC, forced vital capacity; DLCO, diffusion of lung carbon monoxide; TLC, total lung capacity; FEV1, forced expiratory volume in first second.

All QCT indices (with the exception of tSdev) had a good correlation with the Goh and Taouli scores (rho ranges from 0.36 to 0.65; p\<0.001). The QCT indices (except for tSdev) strength of correlation with FVC and DLco ranged from moderate to good (rho from 0.33 to 0.55 and from 0.39 to 0.61, respectively; p\<0.001). Data are reported in [Table 1](#pone.0224772.t001){ref-type="table"}.

Both Goh and Taouli scores had a moderate strength of correlation with FVC (rho = -0.36 and -0.38, respectively; p\<0.004) and with DLco (rho = -0.42 and -0.44, respectively; p\<0.004).

In the SS-ILD group, 44% (16/36) of patients had extensive lung disease (Goh score ≥20%). These patients had similar characteristics to those with limited SS-ILD ([Table 3](#pone.0224772.t003){ref-type="table"}), except for lower FVC and DLco values, and a lower prevalence of nonspecific interstitial pneumonia (69% *vs* 80%).

10.1371/journal.pone.0224772.t003

###### Characteristics of SS-ILD patients with limited *versus* extensive lung disease.

![](pone.0224772.t003){#pone.0224772.t003g}

  -------------------------------------------------------------------------------------------------------------------------------
                                                                      SS-ILD cohort   SS-ILD (limited)   SS-ILD\        p
                                                                                                         (extensive)    
  ------------------------------------------------------------------- --------------- ------------------ -------------- ---------
  N                                                                   36              20                 16             \-

  Age, median (yrs) (95% CI)                                          69\             68\                70\            nss
                                                                      (63--74)        (62--76)           (61--75)       

  Sex (M:F)                                                           4:32            2:18               2:14           nss

  Smoke habit (no:former:yes) [\*](#t003fn002){ref-type="table-fn"}   27:0:7          16:0:3             11:0:4         nss

  Disease duration, median (yrs) (95% CI)                             5\              6\                 4\             nss
                                                                      (3--7)          (3--12)            (1--7)         

  pSS prevalence (%)                                                  72              80                 63             nss

  Onset symptoms (sicca:dyspnoea:other)                               10:20:6         5:11:4             5:9:2          nss

  SSA prevalence (%)                                                  63              70                 56             nss

  SSB prevalence (%)                                                  31              35                 25             nss

  FVC (%)(95% CI) [\*\*](#t003fn003){ref-type="table-fn"}             94\             100\               84\            0.03
                                                                      (83--99)        (86--115)          (73--97)       

  DLCO (%)(95% CI) [\*\*\*](#t003fn004){ref-type="table-fn"}          63\             70\                51\            0.02
                                                                      (53--71)        (61--85)           (47--65)       

  ILD pattern (NSIP:UIP:Other)                                        27:6:3          16.1:3             11:5:0         0.05

  Goh score (95% CI)                                                  12,5\           7.0\               28.5\          \-
                                                                      (7.7--25.3)     (4.0--8.0)         (25.6--46.7)   

  Taouli score (95% CI)                                               8,0\            5.0\               13.0\          \<0.001
                                                                      (5.7--11.0)     (2.2--6.0)         (11.0--13.7)   
  -------------------------------------------------------------------------------------------------------------------------------

Abbreviations: M, male; F, female; CI, confidence interval; pSS, primary SS; ILD, interstitial lung disease; Nss, not statistically significant; FVC, forced vital capacity; DLCO, diffusion of lung CO; TLC, total lung capacity; NSIP, non-specific interstitial pneumonia; UIP, usual interstitial pneumonia.

\* 2/36 missing data

\*\* 7/36 missing data

\*\*\* 13/36 missing data

All QCT indices except tSDev had a different distribution in the SS-ILD *versus* SS without ILD (p\<0.001) group--defining the groups as follows: 0, SS non-affected; 1, SS limited ILD; and 2, SS extensive ILD. After clustering the SS-ILD patients according to ILD extent, the QCT indices (except for tSDev) had a statistically different distribution in the three subgroups ([Fig 1](#pone.0224772.g001){ref-type="fig"} and [Fig 2](#pone.0224772.g002){ref-type="fig"}).

![Quantitative CT indices distribution in Sjögren's syndrome according to non-affected (group 0), limited ILD (group 1) and extensive (group 2) ILD.\
A. Pulmonary kurtosis; B. Pulmonary skewness; C. Pulmonary standard deviation; D. Pulmonary mean lung attenuation.Differences through multiple comparisons. A. Group 0 vs 1, p = 0.011; group 1 vs 2, p = 0.003; group 0 vs 2, p\< 0.001. B. Group 0 vs 1, p = 0.07; group 1 vs 2, p\<0.001; group 0 vs 2, p\< 0.001.C. Group 0 vs 1, p = 0.28; group 1 vs 2, p = 0.12; group 0 vs 2, p\< 0.001.D. Group 0 vs 1, p = NS; group 1 vs 2, p\<0.001; group 0 vs 2, p\< 0.001.](pone.0224772.g001){#pone.0224772.g001}

![Quantitative CT indices distribution in Sjögren's syndrome according to non-affected (group 0), limited ILD (group 1) and extensive (group 2) ILD.\
A. Total kurtosis; B. total skewness; C. Total standard deviation; D. Total mean lung attenuation. Differences through multiple comparisons. A. Group 0 vs 1, p = NS; group 1 vs 2, p = 0.04; group 0 vs 2, p = 0.03. B. Group 0 vs 1, p = 0.001; group 1 vs 2, p\<0.001; group 0 vs 2, p\< 0.001.C. Group 0 vs 1, p = NS; group 1 vs 2, p = 0.004; group 0 vs 2, p\< 0.001.D. Group 0 vs 1, p = NS; group 1 vs 2, p\<0.001; group 0 vs 2, p\< 0.001.](pone.0224772.g002){#pone.0224772.g002}

Of all QCT indices, tSkew and tKurt were the best ones to differentiate ILD pattern, or not, according to AUC, 0.87 (CI95% 0.79--0.94) and 0.84 (CI95% 0.76--0.93), respectively ([Table 4](#pone.0224772.t004){ref-type="table"}).

10.1371/journal.pone.0224772.t004

###### Cut-off point of quantitative indices according to the Youden index, and its corresponding sensitivity and specificity, to diagnosis interstitial lung disease in Sjögren's syndrome.

![](pone.0224772.t004){#pone.0224772.t004g}

  -------------------------------------------------------------------------------------------------------------
             *Cut-off point*   *AUC*   *CI95%*      *Sensitivity (CI95%)*   *Specificity*\     *Best p value*
                                                                            *(CI95%)*          
  ---------- ----------------- ------- ------------ ----------------------- ------------------ ----------------
  pKurt      2.97              0.81    0.73--0.9    0.73(0.6--0.83)         0.81(0.64--0.92)   \<0.001\*

  ^Δ^pMLA    -826.2            0.74    0.64--0.84   0.83(0.67--0.94)        0.58(0.45--0.7)    \<0.001

  ^Δ^pSdev   104.5             0.82    0.73--0.9    0.78 (0.61--0.9)        0.71(0.59--0.82)   \<0.001

  pSkew      1.66              0.8     0.71--0.89   0.74(0.62--0.84)        0.78(0.61--0.9)    \<0.001\*

  pVol       3318.7            0.67    0.55--0.79   0.71(0.59--0.82)        0.64(0.46--0.79)   0.004

  tKurt      7.62              0.84    0.76--0.93   0.85(0.74--0.92)        0.78(0.61--0.9)    \<0.001\*

  tMLA^Δ^    -773.0            0.71    0.6--0.82    0.64(0.46--0.79)        0.73(0.6--0.83)    \<0.001

  tSdev^Δ^   200.6             0.69    0.58--0.79   0.72(0.55--0.86)        0.65(0.52--0.76)   0.002

  tSkew      2.72              0.87    0.79--0.94   0.82(0.7--0.9)          0.81(0.64--0.92)   \<0.001\*

  tVol       2937.08           0.62    0.5--0.75    0.92(0.83--0.97)        0.42(0.26--0.59)   0.04
  -------------------------------------------------------------------------------------------------------------

Abbreviations. ILD, interstitial lung disease; p(X), pulmonary quantitative indices, t(X), total quantitative indices. Kurtosis (Kurt), Sweetness (Skew), standard deviation (Sdev), volume (Vol) and mean lung attenuation (MLA).

\* Both pKurt/pSkew and tKurt/tSkew, were statistically equivalent. ^*Δ*^ Assuming normal pulmonary patterns.

Discussion {#sec009}
==========

To the best of our knowledge, this is the first study showing that QCT indices can characterize subjects with SS -ILD as compared to the standard visual semi-quantitative methods.

Pulmonary manifestations in SS (e.g., asthenia, cough, dyspnea) are variable in intensity and severity, and are often present before a diagnosis of SS is made. The prevalence of lung involvement in SS reported in different series ranges from 12 to 61%, which underscores the clinical necessity of a correct diagnosis \[[@pone.0224772.ref021]\]. Moreover, abnormalities in pulmonary parenchyma can be found in up to 50% of cases and an abnormal pulmonary function test typically reflects a restrictive (lung) rather than an obstructive (airways) pattern \[[@pone.0224772.ref009]\]. Whereas a reduction in DLco is generally the most common abnormality, pulmonary function tests are frequently unable to correctly describe lung involvement in SS--being more accurate in the advanced stage of the disease--and hence have poor sensitivity to detect subclinical pulmonary involvement. Accordingly, HRCT quantification could be useful for monitoring disease, its evolution and response to therapies. The QCT indices described here provide an operator-independent assessment of lung involvement by ILD, as compared with the Taouli and Goh scores, which are operator-dependent. Indeed, the latter score results might be ambiguous in a proportion of cases, even when combined with abnormalities in pulmonary function tests, and may be unable to correctly classify some cases in the corresponding category of severity. By contrast, QCT measurements have proven to provide highly accurate and reproductible diagnoses \[[@pone.0224772.ref015]\], although they require some level of training to follow a standardized imaging acquisition protocol. Moreover, fully automated QCT measurements could eliminate intra- and interobserver variability, particularly when used in diagnostic decision making.

The performance of QCT indices has been previously explored in other autoimmune diseases such as systemic sclerosis (SSc). For instance, in a recent series by Ariani et al., the authors reported a moderate-to-good agreement of all values for ILD associated with SSc, and also in cases with extensive or limited lung disease. Some pulmonary function tests also showed a relatively good correlation with QCT indices (FVC and DLco \<70%) (16). Moreover, QTC indices could distinguish between high and low mortality groups \[[@pone.0224772.ref022]\] in those cases of SSc with ILD, in relation to 1-year mortality prediction clinical scales such as ILD-GAP score (ILD subtype, gender, age, FVC and DLco) or dBi (age, history of respiratory hospitalization, and FVC value and its change after 6 months).

Few studies have quantified pulmonary fibrosis related to SS. In the present study, we compared, for the first time, a QCT analysis of lung involvement against a specific SQCT score (Taouli) and a generic SQCT score (Goh) developed for secondary pulmonary fibrosis. The Goh score, which has been validated in SSc \[[@pone.0224772.ref013],[@pone.0224772.ref023]\] and rheumatoid arthritis \[[@pone.0224772.ref024]\], here it shows excellent correlation with the more complex Taouli score. Hence, the Goh score appears a suitable method also for the quantification of SS-ILD. Likewise, it is reasonable to presume that the Goh score might have a similar predictive value for mortality \[[@pone.0224772.ref025], [@pone.0224772.ref026]\].

Although used as the only laboratory criteria, serologic/immunological parameters are not a definitive guide to diagnosis or to monitor the severity of ILD in SS, and the correlations across different studies are heterogenous. Indeed, we failed to find any significant association between QTC indices and anti-Ro, anti-La or ANA titers. However, anti-Ro/SSA titers were low in the general cohort but were higher in the ILD cohort.

The influence of the principal immunological markers on SS disease diagnosis was recently addressed by Brito-Zerón and colleagues using a Big Data analysis approach in 10,500 patients \[[@pone.0224772.ref027]\]. Regarding the phenotypes of patients, the frequency of the immunological markers ANA, Ro and La were quite similar in the pulmonary domain of the ESSDAI (approximately 10%) at diagnosis. When the authors analyzed the impact of three combinations of anti-Ro/La antibodies, no statistically differences were found in the pulmonary domain. These analyses suggest that novel autoantibodies should be developed to detect ILD with sufficient sensitivity or specificity. The use of more sophisticated profiling should be incorporated as soon as possible in the daily clinical practice, for example, the ratio of blood T cells \[[@pone.0224772.ref028]\], or microRNA profiles \[[@pone.0224772.ref029]\].

In a cross-sectional study aimed to evaluate the prevalence of respiratory symptoms in SS, Kampolis et al. found that up to 20% of all cases were affected \[[@pone.0224772.ref010]\]. As described in the aforementioned study, it is important to differentiate those respiratory symptoms/complaints that have an onset prior to SS diagnosis, such as any underlying respiratory disease--chronic obstructive pulmonary disease, bronchial asthma, or upper chronic airway cough--as approximately one-third of these cases had an established chronic respiratory disease that preceded the onset of SS. Along this line, the impact of smoking (or former smokers) is not infrequent; however, it should be differentiated from symptoms directly related to pulmonary involvement in SS. In some selected cases, however, both diseases could coexist in smokers with SS. Interestingly, the same authors did not report any specific alterations in pulmonary function tests (FEV~1~, FVC, ratio FEV/FVC, DLco) in those patients with pulmonary disease and SS. In our series, there were some missing data for smoking habit in a small percentage of patients (\<10%). Thus, we believe that the issue concerning smoking habit does not significantly impact our results.

Theoretically, pulmonary function tests might not be substantially modified in ILD in SS until the disease is more advanced. Regarding this issue, lung ultrasound showed a good performance when compared with high-resolution thorax CT \[[@pone.0224772.ref030]\]. Indeed, this modality could be potentially useful to detect ILD earlier in SS, independently of the patient's complaints; however, more research is needed to better understand the precise use of ultrasound as an imaging tool for identification of ILD and SS.

Our study has some limitations that should be considered, such as its retrospective design. Also, the CT protocols might be not homogenous across the participating centers--although the percentage of pulmonary disease in the global series fits well with recent data. Some differences could be expected in the immunological profile between ethnic groups and may affect the prevalence of ILD in our series \[[@pone.0224772.ref031]\]. Also, some degree of variable conditions when performing the CT images across the participating centers should be assumed--for example, a degree of heterogenicity in multiple slices and time points \[[@pone.0224772.ref032]\]. Another limitation is that while the reported pulmonary functional tests did not show obstructive profiles in most of the cases, FVC and DLco were not performed in all enrolled cases. Pulmonary function tests were often not requested at the same time as CT by the physicians. The reasons for this irregularity might be that they are not systematically assessed in SS in daily practice--considering they are likely not sufficient to help the clinician assess the extent of the ILD, or its severity. Some other biological/immunological profiles, such as cryoglobulinemia \[[@pone.0224772.ref008],[@pone.0224772.ref027]\], were not collected. Our pooled analysis included primary and secondary SS, and this might impact on the QCT indices and patterns of ILD \[[@pone.0224772.ref033]\]. Finally, the QCT scores might be also influenced by the differences in ILD patterns in SS, such as bronchiolitis, bronchiectasis, non-specific interstitial pneumonia, usual interstitial pneumonia, lymphocytic interstitial pneumonitis, or organizing pneumonitis, among others.

QTC indices are becoming a useful tool in imaging analyses because they improve consistency of imaging diagnosis and might aid the treatment decisions in patients with ILD. This method is also promising for patient stratification according to ILD severity and extent \[[@pone.0224772.ref011], [@pone.0224772.ref022], [@pone.0224772.ref025], [@pone.0224772.ref026], [@pone.0224772.ref034]\]. In clinical practice, a quantitative ILD assessment with a user-friendly staging system (i.e., QCT index) could improve the outcomes of proposed SS-ILD treatments \[[@pone.0224772.ref035], [@pone.0224772.ref036]\].

Finally, the operator-independent algorithm we used in this study is free and time-saving. Accordingly, this method might be extremely suitable for multi-center trials focused on ILD. QCT indices are a promising alternative to visual scorings in ILD related to autoimmune diseases such as SS. We believe that this innovative tool will open new horizons for research into SS, as it has the capability to select ILD patients with extensive lung impairment and, correspondingly, a worse prognosis. QTC indices might potentially represent a pivotal tool at the time of diagnosis, and through management of ILD associated with SS.

We thank K. McCreath for editorial support.
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21 Aug 2019

PONE-D-19-20968

Quantitative assessment of interstitial lung disease in Sjögren's syndrome.

PLOS ONE

Dear Dr. Guisado-Vasco,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specifically, both reviewers found out some interests in this study, but also pointed out a number of criticisms that require improvement or even amendment. I ask the authors to fully respond to all points made by reviewers.

We would appreciate receiving your revised manuscript by Oct 05 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Masataka Kuwana, MD, PhD

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for stating the following in the Competing Interests section:

Prof. Carlo Vancheri is part of F. Hoffmann-La Roche Ltd. Scientific Board. He has received consulting fees and/or speaker fees from Astrazeneca, Boehringer Ingelheim, Chiesi, F. Hoffmann-La Roche Ltd and Menarini.

Prof. Stefano Palmucci has reveived personal fees and honoraria for lectures from Boehringer Ingelheim, Delphi International srl and F. Hoffmann-La Roche Ltd. He has been included in the scientific board for Boehringer Ingelheim.

None of the other authors have any potential conflicts of interest to disclose in relation to this work.

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors reported quantitative assessment of interstitial lung disease in Sjögren's syndrome. It is interesting to focus the usefulness of quantitative CT in Sjögren's syndrome-ILD, but I have some major concerns about the data

Major;

1\. CTD-ILD and quantitative CT scores have already been studied, but most patients were scleroderma. Therefore, it was very interesting to examine the quantitative CT score for Sjogren\'s syndrome in a large number of people. However, only association between CT analysis by histogram and ILD type are not appropriate as a paper.

Regarding scleroderma, CT scores and prognosis have already been examined. Did you classify ILD as limited and extensive, but was it related to prognosis as well as scleroderma? You need to consider if CT score affects prognosis in Sjogren\'s syndrome.

2\. The percentage of patients with pSS-ILD is 72% (Table 1).

The secondary SS needs to be described in detail.

3\. It seems necessary to create a table of correlation between quantitative CT analysis and clinical findings, respiratory function tests, and semi-quantitative CT analysis.

Minor

1.The figure is difficult to see and should be considered.

2 .In figure1. 2, the statistical differences between the three groups need to be clearly stated.

Reviewer \#2: The authors reported the usefulness of quantitative chest computed tomography

(QCT) assessment of interstitial lung disease (ILD) in patients with Sjögren's syndrome (SS). In this multi-center and retrospective study, QCT indices identified patients with SS and ILD (SS-ILD), and discriminated those with lesser or greater lung disease.

This is an important study that demonstrates that QCT indices can characterize subjects with SS-ILD in comparison to the standard visual, semi-quantitative methods such as Goh and Taouli scoring.

Major

1\. This study showed that QCT indices discriminated the severity of ILD in patients with SS. However, optimal cut-off points for each indicator were not determined. How QCT indices can be utilized in future research.

2\. With respect to Taouli scores, in their original paper (Eur Radiol 2002; 12:1504-1511), the authors calculated scores including ground-glass attenuation, honeycombing, centrilobular nodules, reticular pattern, mosaic perfusion, and air trapping. In the present study, how were the Taouli scores determined ?

Minor

1\. There were no descriptions of the correlation between QCT indices and the Goh and Taouli scores or pulmonary function test findings in Table 1. Please modify the descriptions.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0224772.r002

Author response to Decision Letter 0

26 Sep 2019

Dear Editor,

Thank you for considering our manuscript, 'Quantitative assessment of interstitial lung disease in Sjögren's syndrome' (PONE-D-19-20968), sent to PLOS One.

We really appreciate the opportunity to review our manuscript in order to fully address your concerns and comments of the referee.

Then, we are going to address point by point the reviewer's recommendations.

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

I have reviewed the POLS ONE's style guidelines, as you pointed out.

First, I have added a title page to the manuscript body, according to the format recommended by your editorial office.

Second, I have done some changes in the body of the template/manuscript according to them -mainly headings, as required.

2\. Thank you for stating the following in the Competing Interests section:

Prof. Carlo Vancheri is part of F. Hoffmann-La Roche Ltd. Scientific Board. He has received consulting fees and/or speaker fees from Astrazeneca, Boehringer Ingelheim, Chiesi, F. Hoffmann-La Roche Ltd and Menarini.

Prof. Stefano Palmucci has reveived personal fees and honoraria for lectures from Boehringer Ingelheim, Delphi International srl and F. Hoffmann-La Roche Ltd. He has been included in the scientific board for Boehringer Ingelheim.

None of the other authors have any potential conflicts of interest to disclose in relation to this work.

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

I confirm, it does not alter the conflict of interest policy of your journal. I have added the following sentence, as recommended: 'This does not alter our adherence to PLOS ONE policies on sharing data and materials'.

Reviewer \#1: The authors reported quantitative assessment of interstitial lung disease in Sjögren's syndrome. It is interesting to focus the usefulness of quantitative CT in Sjögren's syndrome-ILD, but I have some major concerns about the data

Major;

1\. CTD-ILD and quantitative CT scores have already been studied, but most patients were scleroderma. Therefore, it was very interesting to examine the quantitative CT score for Sjogren\'s syndrome in a large number of people. However, only association between CT analysis by histogram and ILD type are not appropriate as a paper.

Regarding scleroderma, CT scores and prognosis have already been examined. Did you classify ILD as limited and extensive, but was it related to prognosis as well as scleroderma? You need to consider if CT score affects prognosis in Sjogren\'s syndrome.

Before any new diagnostic technique can be used as an outcome measurement instrument, it should be tested its reliability comparing to actual standards. It is the aim of the present research. Later, it could be used as a prognostic tool -- it is our next step in the research. In fact, the development of the quantitative indices in systemic sclerosis followed up the same idea of our working group -- the count with some members whose developed this scoring system in scleroderma. First, it was release a publication assessing the reliability of these indices (2015), and them, a model of prediction of mortality was developed (2017).

References

Jousse-Joulin S, et al. Video clip assessment of a salivary gland ultrasound scoring system in Sjögren's syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise. Ann Rheum Dis 2019;78:967--973

Ariani A et al. Operator-independent quantitative chest computed tomography versus standard assessment of interstitial lung disease related to systemic sclerosis: a multi-center study. Mod Rheumatol 2015; 25(5):724-30.

Ariani A et al. Quantitative chest computed tomography is associated to two prediction models of mortality in interstitial lung disease related to systemic sclerosis. Rheumatology (Oxford), 2017; 56(6): 922-927.

2\. The percentage of patients with pSS-ILD is 72% (Table 1). The secondary SS needs to be described in detail.

A paragraph was added at the beginning of the results section, detailing the diseases associated to SS.

The diseases associated to the development of SS, secondary SS, were: rheumatoid arthritis (5,9%), systemic lupus erythematosus (2%), systemic sclerosis (12,7%), and undifferentiated connective tissue disease (9,8%). Not all cases were affected of ILD, of course: just 10 have secondary SS.

3\. It seems necessary to create a table of correlation between quantitative CT analysis and clinical findings, respiratory function tests, and semi-quantitative CT analysis.

This table has been inserted in the text -- previously it was designed as supplementary material. It has been named as table 2. Hence, the former table 2 as labeled now as table 3.

Minor

1.The figure is difficult to see and should be considered.

The figures have been edited and introduced some changes to maximize its resolution.

2 .In figure1. 2, the statistical differences between the three groups need to be clearly stated.

Thank you very much for this comment. In order to a better understanding and simplified of the images, it has been added a footnote in both set of figures, which explains the differences between every group (0,1,2), and corresponding p-values.

Reviewer \#2: The authors reported the usefulness of quantitative chest computed tomography

(QCT) assessment of interstitial lung disease (ILD) in patients with Sjögren's syndrome (SS). In this multi-center and retrospective study, QCT indices identified patients with SS and ILD (SS-ILD), and discriminated those with lesser or greater lung disease.

This is an important study that demonstrates that QCT indices can characterize subjects with SS-ILD in comparison to the standard visual, semi-quantitative methods such as Goh and Taouli scoring.

Major

1\. This study showed that QCT indices discriminated the severity of ILD in patients with SS. However, optimal cut-off points for each indicator were not determined. How QCT indices can be utilized in future research.

It was inserted/added a new table (number 4) to sum up these cut-off points, according to the Youden index applying using the model of area under the curve. A brief comment has been inserted in the results section.

I am agreeing with the point, that these cut-off points could be use in the next step of the research as predictive models of mortality in ILD related to SS.

2\. With respect to Taouli scores, in their original paper (Eur Radiol 2002; 12:1504-1511), the authors calculated scores including ground-glass attenuation, honeycombing, centrilobular nodules, reticular pattern, mosaic perfusion, and air trapping. In the present study, how were the Taouli scores determined ?

These scores were calculating by two expert radiologists, properly trainee in semiquantitative scores. Hence, the score was calculated by the sum of all the categories that represent lung fibrosis, namely: honeycombing, reticular pattern, and ground-glass attenuation.

Minor

1\. There were no descriptions of the correlation between QCT indices and the Goh and Taouli scores or pulmonary function test findings in Table 1. Please modify the descriptions.

A new table (Table 2) has been inserted where the correlations are described as recommended. It is mentioned in the results paragraph.

We hope that these comments and improvements have fulfilled the referees' recommendations.

Such way, your editorial office could consider the current version of the manuscript for its final acceptance.

If there are any further questions or comments after this revision, please do not hesitate to contact us.

Sincerely,

Pablo Guisado Vasco

###### 

Submitted filename: Response to reviewers v.1.0.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0224772.r003
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22 Oct 2019

Quantitative assessment of interstitial lung disease in Sjögren's syndrome.

PONE-D-19-20968R1

Dear Dr. Guisado-Vasco,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Masataka Kuwana, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: Thank you for addressing my comments from initial review.The data are potentially interesting and worthy of evaluation for SS-ILD.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

10.1371/journal.pone.0224772.r004
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Masataka Kuwana

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1 Nov 2019

PONE-D-19-20968R1

Quantitative assessment of interstitial lung disease in Sjögren's syndrome

Dear Dr. Guisado-Vasco:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Masataka Kuwana

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**Prof. Carlo Vanchieri is part of F. Hoffmann-La Roche Ltd. Scientific Board. He has received consulting fees and/or speaker fees from Astrazeneca, Boehringer Ingelheim, Chiesi, F. Hoffmann-La Roche Ltd and Menarini. Prof. Stefano Palmucci has reveived personal fees and honoraria for lectures from Boehringer Ingelheim, Delphi International srl and F. Hoffmann-La Roche Ltd. He has been included in the scientific board for Boehringer Ingelheim. This does not alter our adherence to PLOS ONE policies on sharing data and materials. None of the other authors have any potential conflicts of interest to disclose in relation to this work.

[^2]: ‡ These authors also contributed equally to this work.
